铅-203 VMT-α-神经内分泌肿瘤闪烁成像：一种前景广阔的治疗药物。

IF 0.4 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Indian Journal of Nuclear Medicine Pub Date : 2024-03-01 Epub Date: 2024-05-29 DOI:10.4103/ijnm.ijnm_2_23

Parul Thakral, Ishita Barat Sen, Subha Shankar Das, Michael K Schultz, Jyotsna Kumari, C B Virupakshappa, Dharmender Malik

{"title":"铅-203 VMT-α-神经内分泌肿瘤闪烁成像：一种前景广阔的治疗药物。","authors":"Parul Thakral, Ishita Barat Sen, Subha Shankar Das, Michael K Schultz, Jyotsna Kumari, C B Virupakshappa, Dharmender Malik","doi":"10.4103/ijnm.ijnm_2_23","DOIUrl":null,"url":null,"abstract":"Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.","PeriodicalId":45830,"journal":{"name":"Indian Journal of Nuclear Medicine","volume":"39 2","pages":"142-143"},"PeriodicalIF":0.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232724/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.\",\"authors\":\"Parul Thakral, Ishita Barat Sen, Subha Shankar Das, Michael K Schultz, Jyotsna Kumari, C B Virupakshappa, Dharmender Malik\",\"doi\":\"10.4103/ijnm.ijnm_2_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.\",\"PeriodicalId\":45830,\"journal\":{\"name\":\"Indian Journal of Nuclear Medicine\",\"volume\":\"39 2\",\"pages\":\"142-143\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232724/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijnm.ijnm_2_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijnm.ijnm_2_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

使用铅-212（Pb-212）标记的肽进行靶向α治疗（TAT）是治疗转移性神经内分泌肿瘤（NET）的一个极具吸引力的选择。由于 Pb-203 是 Pb-212 的精确诊断替代物，因此用 Pb-203 标记肽进行成像是评估用 Pb-212 标记制剂进行 TAT 可行性的重要前提。在此，我们展示了一位转移性NET患者使用Pb-203 VMT-α-NET（一种体生长抑素受体靶向药物）的成像数据，并展示了Pb-203 VMT-α-NET与Ga-68 DOTANOC的匹配分布。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent.

Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Nuclear Medicine RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

0.70

自引率

0.00%

发文量